Takuji Iwase

Takuji Iwase

Auto-generated profile, based on publicly available information

Takuji Iwase

Cancer Institute Hospital

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 February 2012 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
STShunji Takahashi
Shunji Takahashi
TITakuji Iwase
Takuji Iwase
NKNorio Kohno
Norio Kohno
TITakashi Ishikawa
Takashi Ishikawa
TTTetsuya Taguchi
Tetsuya Taguchi
SNShinzaburo Noguchi
Shinzaburo Noguchi

20 June 2023 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
TITakuji Iwase
Takuji Iwase
SSShigehira Saji
Shigehira Saji
KIKotaro Iijima
Kotaro Iijima
KHKenji Higaki
Kenji Higaki
SOShoichiro Ohtani
Shoichiro Ohtani
HMHirofumi Mukai
Hirofumi Mukai
PURPOSE: Treatment with an aromatase inhibitor for 5 years is the standard treatment for postmenopausal hormone receptor–positive breast cancer. We investigated the effects of extending this treatment to 10 years on disease-free survival (DFS). PATIENTS AND METHODS: This prospective, randomized, multicenter open-label phase III study assessed the effect of extending anastrozole treatment for an additional 5 years in postmenopausal patients who were disease-free after treatment with either 5 years of anastrozole alone or 2-3 years of tamoxifen followed by 2-3 years of anastrozole. Patients were allocated randomly (1:1) to continue anastrozole for an additional 5 years or stop anastrozole. The primary end point was DFS, including breast cancer recurrence, second primary cancers, and death from any cause. This study is registered with University Hospital Medical Information Network, Japan (UMIN) clinical trials registry (UMIN000000818). RESULTS: We enrolled 1,697 patients from 117 facilities between November 2007 and November 2012. Follow-up information was available for 1,593 patients (n = 787 in the continue group, n = 806 in the stop group), who were defined as the full analysis set, including 144 patients previously treated with tamoxifen and 259 patients who underwent breast-conserving surgery without irradiation. The 5-year DFS rates were 91% (95% CI, 89 to 93) in the continue group and 86% (95% CI, 83 to 88) in the stop group (hazard ratio, 0.61; 95% CI, 0.46 to 0.82; P < .0010). Notably, extended anastrozole treatment reduced the incidence of local recurrence (continue group, n = 10; stop group, n = 27) and second primary cancers (continue group, n = 27; stop group, n = 52). There was no significant difference in overall or distant DFS. Menopausal or bone-related all-grade adverse events were more frequent among patients in the continue group than those in the stop group, but the incidence of grade ≥3 adverse events was <1% in both groups. CONCLUSION: Continuing adjuvant anastrozole for an additional 5 years after 5 years of initial treatment with anastrozole or tamoxifen followed by anastrozole was well tolerated and improved DFS. Although no difference in overall survival was observed as in other trials, extended anastrozole therapy could be one treatment choice in postmenopausal patients with hormone receptor–positive breast cancer.

4 February 2012 in Breast Cancer
Verified
Journal Article
Closed access
PDF file
NHNaoko Honma
Naoko Honma
RHRie Horii
Rie Horii
TITakuji Iwase
Takuji Iwase
SSShigehira Saji
Shigehira Saji
MYMamoun Younes
Mamoun Younes
FAFutoshi Akiyama
Futoshi Akiyama

24 August 2015 in Translational Oncology
Verified
Journal Article
Open access
AKAnna Kiyomi
Anna Kiyomi
MMMasujiro Makita
Masujiro Makita
TOTomoko Ozeki
Tomoko Ozeki
NLNa Li
Na Li
ASAiko Satomura
Aiko Satomura
俊平俊 彦 平野
俊 彦 平野
Several cytokines secreted from breast cancer tissues are suggested to be related to disease prognosis. We examined Th1/Th2/Th17 cytokines produced from three-dimensionally cultured breast cancer tissues and related them with patient clinical profiles. 21 tumor tissues and 9 normal tissues surgically resected from breast cancer patients were cultured in thermoreversible gelatin polymer-containing medium. Tissue growth and Th1/Th2/Th17 cytokine concentrations in the culture medium were analyzed and were related with hormone receptor expressions and patient clinical profiles. IL-6 and IL-10 were expressed highly in culture medium of both cancer and normal tissues. However, IFN-γ, TNF-α, IL-2, and IL-17A were not detected in the supernatant of the three-dimensionally cultured normal mammary gland and are seemed to be specific to breast cancer tissues. The growth abilities of hormone receptor-negative cancer tissues were significantly higher than those of receptor-positive tissues (P=0.0383). Cancer tissues of stage ≥IIB patients expressed significantly higher TNF-α levels as compared with those of patients with stage <IIB (P=0.0096). The tumor tissues resected from breast cancer patients can grow in the three-dimensional thermoreversible gelatin polymer culture system and produce Th1/Th2/Th17 cytokines. Hormone receptor-positive cancer tissues showed less growth ability. TNF-α is suggested to be a biomarker for the cancer stage.

6 January 2013 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
MIMakoto Ishitobi
Makoto Ishitobi
YOYasuhiro Okumura
Yasuhiro Okumura
NANobuyuki Arima
Nobuyuki Arima
AYAtsushi Yoshida
Atsushi Yoshida
KNKatsuhiko Nakatsukasa
Katsuhiko Nakatsukasa
HIHideo Inaji
Hideo Inaji

16 April 2024 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
AOAkiko Ogiya
Akiko Ogiya
KKKiyomi Kimura
Kiyomi Kimura
TUTakayuki Ueno
Takayuki Ueno
TITakuji Iwase
Takuji Iwase
SOShinji Ohno
Shinji Ohno